NCT00186394

Brief Summary

To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Apr 2000

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2000

Completed
5.5 years until next milestone

First Submitted

Initial submission to the registry

September 13, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 16, 2005

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2006

Completed
Last Updated

July 27, 2010

Status Verified

July 1, 2010

Enrollment Period

6.7 years

First QC Date

September 13, 2005

Last Update Submit

July 23, 2010

Conditions

Lymphoma, Non-HodgkinBlood and Marrow Transplant (BMT)Lymphomas: Non-Hodgkin

Outcome Measures

Primary Outcomes (3)

  • Safety

  • Toxicity

  • Efficacy

Secondary Outcomes (1)

  • Incidence of acute and chronic GVHD

Interventions

ablative allogeneic hematopoietic cell transplantationPROCEDURE

Eligibility Criteria

Age18 Years - 61 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age: \>18 and \<61 years of age

You may not qualify if:

  • Serum creatinine of \> 2 mg/dl or creatinine clearance \< 60 ml/min
  • Diseases other than non-Hodgkin's lymphoma
  • Prior bone marrow transplant procedure
  • Severe psychological or medical illness

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University School of Medicine

Stanford, California, 94305, United States

Location

MeSH Terms

Conditions

Lymphoma, Non-Hodgkin

Condition Hierarchy (Ancestors)

LymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Wen-Kai Weng

    Stanford University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 16, 2005

Study Start

April 1, 2000

Primary Completion

December 1, 2006

Study Completion

December 1, 2006

Last Updated

July 27, 2010

Record last verified: 2010-07

Locations

US(1)